We are live on ! Find out more
ECM

Endurant Capital Management Portfolio holdings

AUM $17.4M
1-Year Est. Return 7.38%
This Fund
S&P 500
This Quarter Est. Return
+1.82%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$330M
AUM Growth
-$23.6M
Cap. Flow
-$25.7M
Cap. Flow %
-7.79%
Top 10 Hldgs %
34.6%
Holding
110
New
18
Increased
26
Reduced
40
Closed
25

Top Buys

Rank Stock Value
1
SBRA icon
Sabra Healthcare REIT
SBRA
+$12.6M
2
DHR icon
Danaher
DHR
+$11.5M
3
MD icon
Pediatrix Medical
MD
+$8.38M
4
JNJ icon
Johnson & Johnson
JNJ
+$7.49M
5
TVTY
Tivity Health, Inc. Common Stock
TVTY
+$5.94M

Top Sells

Rank Stock Value
1
BDX icon
Becton Dickinson
BDX
+$8.41M
2
UNH icon
UnitedHealth
UNH
+$6.51M
3
BCR
CR Bard Inc.
BCR
+$6.28M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$6.22M
5
TMO icon
Thermo Fisher Scientific
TMO
+$5.98M

Sector Composition

Rank Sector Weight
1 Healthcare 82.72%
2 Real Estate 3.7%
3 Financials 2.96%
4 Industrials 0.94%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IRTC icon
51
iRhythm Holdings
IRTC
$3.85B
$2.3M 0.7%
44,300
-121,200
-73% -$5.49M
CVS icon
52
CVS Health
CVS
$133B
$2.24M 0.68%
27,500
-20,800
-43% -$1.65M
GILD icon
53
Gilead Sciences
GILD
$162B
$2.22M 0.67%
27,357
-72,543
-73% -$5.55M
MDT icon
54
Medtronic
MDT
$109B
$2.16M 0.65%
27,739
-11,861
-30% -$985K
HALO icon
55
Halozyme
HALO
$9.79B
$2.01M 0.61%
115,500
-21,400
-16% -$290K
RXDX
56
DELISTED
Ignyta, Inc.
RXDX
$2M 0.61%
161,800
+29,400
+22% +$303K
AGRX
57
DELISTED
Agile Therapeutics
AGRX
$1.97M 0.6%
+221
New +$1.7M
DERM
58
DELISTED
Dermira, Inc.
DERM
$1.75M 0.53%
65,015
-11,473
-15% -$300K
ARA
59
DELISTED
American Renal Associates Holdings, Inc
ARA
$1.44M 0.44%
95,956
+1,548
+2% +$24.3K
BAX icon
60
Baxter International
BAX
$13.5B
$1.3M 0.39%
20,749
+10,849
+110% +$670K
EW icon
61
Edwards Lifesciences
EW
$49.6B
$1.27M 0.38%
34,848
-32,100
-48% -$1.22M
ZBH icon
62
Zimmer Biomet
ZBH
$18.2B
$1.16M 0.35%
+10,197
New +$1.18M
ALDR
63
DELISTED
Alder Biopharmaceuticals
ALDR
$1.12M 0.34%
91,600
+49,300
+117% +$514K
ARRY
64
DELISTED
Array Biopharma Inc
ARRY
$1.12M 0.34%
91,000
+7,300
+9% +$67.8K
DVAX
65
DELISTED
Dynavax Technologies
DVAX
$1.09M 0.33%
50,500
-9,358
-16% -$148K
FATE icon
66
Fate Therapeutics
FATE
$286M
$1.08M 0.33%
+272,700
New +$927K
WMGI
67
DELISTED
Wright Medical Group Inc
WMGI
$1.02M 0.31%
+39,600
New +$1.09M
EHC icon
68
Encompass Health
EHC
$11B
$1.01M 0.31%
27,408
-12,318
-31% -$439K
RNTX
69
Rein Therapeutics
RNTX
$63.1M
$928K 0.28%
3,468
-987
-22% -$248K
ANAB icon
70
AnaptysBio
ANAB
$1.58B
$860K 0.26%
+24,600
New +$664K
BOLD
71
DELISTED
Audentes Therapeutics, Inc
BOLD
$819K 0.25%
29,235
+35
+0.1% +$760
NVTA
72
DELISTED
Invitae Corporation
NVTA
$798K 0.24%
+85,200
New +$809K
KITE
73
DELISTED
Kite Pharma, Inc.
KITE
$737K 0.22%
4,100
-12,300
-75% -$1.71M
ZSAN
74
DELISTED
Zosano Pharma Corporation
ZSAN
$681K 0.21%
1,182
+109
+10% +$79.9K
ASND icon
75
Ascendis Pharma A/S
ASND
$16B
$628K 0.19%
+17,330
New +$497K
1 2
3
4 5

Similar funds

VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
HSCU
Half Sky Capital (UK) London, United Kingdom $30.5M AUM 67.32% 1-Year Est. Return

Endurant Capital Management's Q3 2017 Portfolio in Review

As of Q3 2017, Endurant Capital Management held 110 positions worth $330M, down 6.7% from $354M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Endurant Capital Management withdrew a net $25.7M in Q3 2017, closing 25 positions and reducing 40 holdings. Its most notable exit was K2M Group Holdings, Inc, an estimated $3.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 88% a quarter earlier, followed by Real Estate and Financials.

Against the trend, Endurant Capital Management opened a new position in Sabra Healthcare REIT worth $12.2M.

  • Endurant Capital Management's largest Q3 2017 buy was Sabra Healthcare REIT: 556,330 shares worth $12.2M.
  • Endurant Capital Management added most to Tivity Health, Inc. Common Stock in Q3 2017, an estimated $5.94M increase.
  • Endurant Capital Management's biggest Q3 2017 reduction was Becton Dickinson, cutting an estimated $8.41M.
  • Endurant Capital Management fully exited K2M Group Holdings, Inc in Q3 2017, selling an estimated $3.4M.
  • Endurant Capital Management's ten largest holdings make up 35% of its $330M portfolio in Q3 2017.
  • Endurant Capital Management opened 18 new positions and closed 25 in Q3 2017.
  • Endurant Capital Management's portfolio value fell 6.7% quarter-over-quarter to $330M.

Based on Endurant Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.